Skip to main content
SpringerLink
Log in

PI3K-mTOR in Cancer and Cancer Therapy

  • Book
  • © 2016

Overview

Editors:
  1. Nandini Dey

    1. Oncology, Head of Cancer Biology, Avera Cancer Instit Center for Precision, SIOUX FALLS, USA

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  2. Pradip De

    1. Oncology, Head of Translational Oncology, Avera Cancer Institute Center for Preci, Sioux Falls, USA

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  3. Brian Leyland-Jones

    1. Precision Oncology,, Avera Cancer Institute Center for, Sioux Falls, USA

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  • Provides a comprehensive review of recent developments made in the basic science and the exciting new therapeutic strategies of the PI3K-mTOR pathway-related signal transduction
  • Examines the contribution of the PI3K-AKT-mTOR signaling pathway towards the development and the progression of human tumors
  • Includes two complementary sections which address the problem of etiology and disease progression?
  • Includes supplementary material: sn.pub/extras

Part of the book series: Cancer Drug Discovery and Development (CDD&D)

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (9 chapters)

  1. Front Matter

    Pages i-xxiv
    Download chapter PDF

  2. PI3K-Akt-mTOR Signaling in Cancer and Cancer Therapeutics

    • Sameer S. Chopra, Lewis C. Cantley
    Pages 1-25

  3. PI3K-mTOR Pathway in Cancers

    1. Front Matter

      Pages 27-27
      Download chapter PDF

    2. The mTOR Complexes in Cancer Cell Metabolism

      • Thomas Lynch, Joseph G. Moloughney, Estela Jacinto
      Pages 29-63

    3. PI3K-AKT-mTOR Pathway Cooperates with the DNA Damage Repair Pathway: Carcinogenesis in Triple-Negative Breast Cancers and Beyond

      • Pradip De, Jennifer H. Carlson, Brian Leyland-Jones, Nandini Dey
      Pages 65-108

    4. The AKT-mTOR Signaling Pathway for Drug Response Prediction and Prognostic Signatures

      • John Conor Moran, Elisa Baldelli, Emanuel F. Petricoin, Mariaelena Pierobon
      Pages 109-124

    5. Resistance to PI3K Pathway Inhibition

      • Payal D. Shah, Sarat Chandarlapaty
      Pages 125-147

  4. PI3K-mTOR Pathway in Cancer Medicine

    1. Front Matter

      Pages 149-149
      Download chapter PDF

    2. Combination Therapies Targeting the PI3K/AKT/mTOR Pathways

      • Aung Naing, Gordon B Mills, Funda Meric-Bernstam
      Pages 151-180

    3. Phospho-Inositol-3-Kinase Activity and Dysregulation in Pediatric Leukemia and Lymphoma

      • Charles B Goodwin, Rebecca J. Chan
      Pages 181-229

    4. HER2 Signaling Network in Advanced Breast Cancer: Opportunities for Combination Therapies

      • Nandini Dey, Brian Leyland-Jones, Pradip De
      Pages 231-261

    5. The PI3K-mTOR Pathway in Prostate Cancer: Biological Significance and Therapeutic Opportunities

      • Jason Boyang Wu, Leland W.K. Chung
      Pages 263-289

  5. Back Matter

    Pages 291-294
    Download chapter PDF
Back to top

Keywords

About this book

In the post human-genome project era, cancer specific genomic maps are redesigning tumor taxonomy by evolving from histopathology to molecular pathology. The success of a cancer drug today is fundamentally based on the success in identifying target genes that control beneficial pathways. The overwhelming power of genomics and proteomics has enlightened researchers about the fact that the PI3K-mTOR pathway is the most commonly up-regulated signal transduction pathway in various cancers, either by virtue of its activation downstream of many cell surface growth factor receptors or by virtue of its collateral and compensatory circuitry with RAS-MAPK pathway. Oncogenic signaling in the majority of solid tumors is sustained via the PI3K-AKT-mTOR pathway. Because of its prominent role in many cancer types, the PI3K-mTOR pathway has become a major therapeutic target. The volume includes two complementary parts which address the problem of etiology and disease progression and is intended to portray the very basic mechanisms of the PI3K-AKT-mTOR signaling pathway’s involvement in various facets of the cancer, including stem cell renewal, cell metabolism, angiogenesis, genetic instability, and drug resistance.   Significant progress has been made in recent years elucidating the molecular mechanism of cancer cell proliferation, angiogenesis, and drug-resistance in relation to the PI3K-mTOR pathway and this volume provides an in-depth overview of recent developments made in this area.​

Editors and Affiliations

  • Oncology, Head of Cancer Biology, Avera Cancer Instit Center for Precision, SIOUX FALLS, USA

    Nandini Dey

  • Oncology, Head of Translational Oncology, Avera Cancer Institute Center for Preci, Sioux Falls, USA

    Pradip De

  • Precision Oncology,, Avera Cancer Institute Center for, Sioux Falls, USA

    Brian Leyland-Jones

About the editors

Nandini Dey, M.S., Ph.D., is a Senior Scientist Head of Cancer Biology, Avera Cancer Institute Center for Precision Oncology. She is also Assistant Professor of the Department of Internal Medicine at The University of South Dakota Sanford School of Medicine. Dey has more than 20 years of experience in translational research and has authored or co-authored more than 80 publications.<

Pradip De, M.S., Ph.D., is a Senior Scientist Head of Translational Oncology, Avera Cancer Institute Center for Precision Oncology. He is also Assistant Professor of the Department of Internal Medicine at The University of South Dakota Sanford School of Medicine. De has more than 20 years of experience in translational research in academics and industry and has authored or co-authored more than 90 publications.

Brian Leyland-Jones, MB BS, Ph.D. is Vice President of Avera Cancer Institute Center for Precision Oncology. Dr. Leyland-Jones is a consulting professor at the Stanford University School of Medicine. He is an internationally renowned breast cancer expert with more than 35 years experience in patient care and research, has published over 170 papers and has received over 11,000 citations in his scientific career.

Bibliographic Information

  • Book Title: PI3K-mTOR in Cancer and Cancer Therapy

  • Editors: Nandini Dey, Pradip De, Brian Leyland-Jones

  • Series Title: Cancer Drug Discovery and Development

  • DOI: https://doi.org/10.1007/978-3-319-34211-5

  • Publisher: Humana Cham

  • eBook Packages: Medicine, Medicine (R0)

  • Copyright Information: Springer Science+Business Media New York 2016

  • Hardcover ISBN: 978-3-319-34209-2Published: 22 June 2016

  • Softcover ISBN: 978-3-319-81704-0Published: 31 May 2018

  • eBook ISBN: 978-3-319-34211-5Published: 10 June 2016

  • Series ISSN: 2196-9906

  • Series E-ISSN: 2196-9914

  • Edition Number: 1

  • Number of Pages: XXIV, 294

  • Number of Illustrations: 31 illustrations in colour

  • Topics: Cancer Research, Molecular Medicine, Drug Resistance

Publish with us

Policies and ethics

Back to top

Search

Navigation